Corporate News

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

CNS continues to make operational progress despite sales headwinds, with the IVDR project on track and further restructuring to maintain a high level of productivity

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces its unaudited interim results for the six months ended 30 September 2026.

Download To view a full version of the results in  PDF format  click here

 

H1 Financial Highlights:

• Revenue decreased to £2.4m (H1 2026: £3.9m)
• Gross margin decreased to 66.4% (H1 2026: 67.7%), largely due to impact of lower sales on fixed elements in gross margin
• Adjusted EBITDA¹ loss of £(0.5)m (H1 2026: profit of £0.1m)
• Loss before tax £0.8m (H1 2026: £0.4m)
• Cash balance £1.9m (H1 2026: £3.6m)

Operational Highlights:

• CNS Lab productivity remains high with year-on-year volume growth
• India sales continuing to grow almost 20% in local currency and 8.5% in sterling
• Restructuring and cost controls have reduced ongoing administration costs by £0.5m year-on-year
• The IVDR project remains on track for submission in Q3 and CNS Lab will be ready to launch in Q4

Outlook:

• As previously forecast, the Company expects full year sales to be lower than the previous year, this is due to a number of headwinds impacting multiple markets
• Policy changes in China have impacted demand in the market, which is expected to be disruptive for several years
• Inflation and cost of living pressures in markets, particularly in the Middle East and Asia have led to a drop in activity and distributors have not adhered to forecasts. It is hoped that these markets will recover in the near future
• Despite the above challenges, the sales pipeline continues to grow as the new team sources new potential opportunities
• The Company is managing its cash proactively with the IVDR development key to spend, whilst another restructure of resources was undertaken in October to ensure sufficient cash remains to fund the business
• Driving new and existing sales remains the primary objective for H2 and the year thereafter

¹Adjusted for exceptional items, amortisation of intangible assets and share based payment charges.

Commenting on the results, Carolyn Rand, Chair, said:

“The first half of this year has continued to present challenges, with economic pressures impacting market activity across several key regions. While India has achieved good growth, other regions fell short of target, which is disappointing.

In response, the Board has acted decisively, executing a further strategic restructuring in October to reduce our fixed cost base, protect our cash runway, and align our operations with current sales volumes.

We have pushed ahead with the IVDR project and believe that this will help differentiate CNS in the market and assist the sales team in increasing sales to existing customers and converting the pipeline of opportunities. We are confident in the long-term future of CNS as we look forward to launching the next generation of Food Sensitivity testing into the market.”

Investor presentation

James Cooper CEO, Ajay Patel CFO, Erik Melgaard Global Sales Director and David Catchpole Head of Customer Success will provide an investor presentation relating to the Interim Results and future plans today at 14:00 GMT. The presentation will be shared on our website in due course.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Contacts: 

Cambridge Nutritional Sciences PLC	www.cnsplc.com
James Cooper, Chief Executive Officer
Ajay Patel, Chief Financial Officer
Cavendish Capital Markets Limited	Tel: 020 7220 0500
Geoff Nash / Teddy Whiley
Nigel Birks / Harriet Ward (ECM)

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.